Drug intelligence / Profile preview

BioTTT001

Development stage: Phase 2
Lead developer: Beijing Bio-Targeting Therapeutics Technology
Modality: Recombinant Proteins and Enzymes, Oncolytic Viruses → Oncolytic Therapeutics
Administration: Intratumoral

Overview

BioTTT001 is a recombinant oncolytic adenovirus 5 (Ad5) encoding non-secreting interleukin-12 (nsIL-12). Upon administration, it specifically infects and replicates in tumor cells, leading to viral-mediated tumor cell lysis. The released virus particles can then infect neighboring tumor cells, amplifying the antitumor effect. The encoded nsIL-12 acts as an agonist to stimulate immune responses within the tumor microenvironment. BioTTT001 is being developed primarily for the treatment of recurrent or progressive high-grade glioma and other malignant solid tumors. It is currently under clinical investigation in Phase 1/2 trials in China[1][2][3][8].

Other names: recombinant human nsIL12 oncolytic adenovirus injection

Targets

IL-12R (Interleukin-12 receptor)

Beyond the preview

Go deeper on BioTTT001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioTTT001.

Explore the full profile